Trial: 202002010

Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Alectinib, Entrectinib, or Vemurafenib Plus Cobimetinib in Patients with Stages I-III Non-Small Cell Lung Cancer with ALK, ROS1, NTRK, or BRAF V600E Molecular Alterations

Phase

II

Principal Investigator

Waqar, Saiama

Disease Site

Lung

Learn more about this study at: clinicaltrials.gov